Indivior PLC (LON:INDV)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 855.59M |
| Revenue (ttm) | 948.94M |
| Net Income (ttm) | -38.34M |
| Shares Out | 124.27M |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | 6.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 882,665 |
| Average Volume | 376,722 |
| Open | 726.50 |
| Previous Close | 732.00 |
| Day's Range | 679.50 - 730.00 |
| 52-Week Range | 548.71 - 1,770.00 |
| Beta | 0.20 |
| RSI | 29.38 |
| Earnings Date | Feb 14, 2025 |
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUB... [Read more]
News
Indivior targets $1.5B peak revenue for Sublocade amid 2025 transition plans
Indivior PLC (INDV) Q4 2024 Earnings Call Transcript
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat
Indivior Plc (NASDAQ: INDV) stock plunged following the company’s fiscal year 2025 guidance that fell short of Street expectations. Addiction and mental illnesses-focused Indivior reported fourth-qua...
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat
Indivior Plc INDV stock plunged following the company's fiscal year 2025 guidance that fell short of Street expectations.
Indivior PLC 2024 Q4 - Results - Earnings Call Presentation
Earnings To Watch: Indivior PLC (INDV) Reports Q4 2024 Result
Earnings To Watch: Indivior PLC (INDV) Reports Q4 2024 Result
UK's Indivior forecasts 17% decline in 2025 revenue
British drugmaker Indivior on Thursday projected a 17% decline in 2025 net revenue at the midpoint of its forecast range, partly hurt by sluggish sales of its film-form medication-assisted therapy for...
Indivior reports Q4 results
Indivior Announces FY and Q4 2024 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024.
Indivior PLC (INDV) Shares Down 0.83% on Feb 19
Indivior PLC (INDV) Shares Down 0.83% on Feb 19
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes
RICHMOND, Va. , Feb. 12, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative...
Two Seas Capital LP Adjusts Position in Indivior PLC
Two Seas Capital LP Adjusts Position in Indivior PLC
Indivior CFO steps down from board after discussions with Oaktree Capital
Indivior (INDV) stock in focus as CFO resigns from board amid pressure from Oaktree Capital Management. Read more here.
BUSINESS LIVE: Wage growth accelerates; Britvic takeover cleared; Capita to cut more staff
Among the companies with reports and trading updates today are Britvic, Capita, Chemring and Indivior.
Indivior PLC (INDV) Trading 3.1% Higher on Nov 19
Indivior PLC (INDV) Trading 3.1% Higher on Nov 19
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...
SCOPIA CAPITAL MANAGEMENT LP Adjusts Stake in Indivior PLC
SCOPIA CAPITAL MANAGEMENT LP Adjusts Stake in Indivior PLC
Indivior jumps amid investor letter, takeover speculation (update)
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
RICHMOND, Va. , Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a lette...
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
RICHMOND, Va., Oct. 30, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), in recognizing Substance Abuse Prevention Month, provides an update on key findings from the last year that demonstrate th...
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript
Indivior PLC (NASDAQ:INDV) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ETCompany ParticipantsJason Thompson - Head, IRMark Crossley -...
Indivior PLC 2024 Q3 - Results - Earnings Call Presentation
Indivior reports Q3 results
Indivior Announces Q3 2024 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024.
Two Seas Capital LP Increases Stake in Indivior PLC
Two Seas Capital LP Increases Stake in Indivior PLC